Takotsubo cardiomyopathy following liver transplantation - a multicenter cohort study.


Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185

Informations de publication

Date de publication:
03 Oct 2024
Historique:
received: 11 06 2024
accepted: 25 09 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: aheadofprint

Résumé

Takotsubo cardiomyopathy (TCM) is an acute, stress-mediated, reversible cardiomyopathy that occurs in the absence of hemodynamically significant coronary artery disease. We aimed to investigate the characteristics and outcomes of patients who developed TCM following liver transplantation (LT) in a multicenter study. Adult patients from six centers across the US who developed TCM according to Mayo Clinic criteria following LT between 2008-2023 were included. Demographics, perioperative and long-term outcomes, and treatment modalities were assessed. Fifty-five patients were included. The center incidence of TCM ranged from 0.1 - 0.5%. The majority were female (54.5%) and Caucasian (87.2%), and median age at transplant was 59 years. The primary etiologies for LT were alcohol-related cirrhosis (49.1%) and metabolic dysfunction-associated steatotic liver disease cirrhosis (21.8%). The median time from LT to TCM diagnosis was 4 days. TCM was associated with a 60.9% reduction in left ventricular ejection fraction (LVEF) from a pretransplant median LVEF of 64.0% to 25.0%. The most common treatment for TCM was diuretics (67.3%) and afterload reduction (54.5%), with only 27.3% of patients requiring vasopressor support. At median follow-up 31.5 months, 1-year and 3-year overall survivals were 86.3% and 69.4%, respectively. Repeat echocardiogram performed at a median of 84 days demonstrated 45/55 patients (81.8%) had recovered LVEF ≥50%. Patients with LVEF recovery to ≥50% had significantly improved overall survival (OS) compared to those without LVEF recovery >50% (106.4 mos vs. 12.2 mos, p=0.001). TCM following LT is associated with a significant reduction in LVEF, however the majority of patients recover LVEF to > 50% with minimal perioperative mortality. Importantly, follow-up assessment of LVEF has significant implications as lack of recovery is associated with worse OS.

Identifiants

pubmed: 39356538
doi: 10.1097/LVT.0000000000000503
pii: 01445473-990000000-00480
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Association for the Study of Liver Diseases.

Auteurs

Abraham J Matar (AJ)

Emory University, Division of Transplantation, Atlanta, Georgia.
University of Minnesota, Division of Transplantation, Minneapolis, Minnesota.

James Keiler (J)

Emory University, Division of Transplantation, Atlanta, Georgia.

Alexandra C Bolognese (AC)

Oregon Health & Science University, Division of Transplantation, Portland, Oregon.

Arielle Cimeno (A)

University of Chicago, Division of Transplantation, Chicago, Illinois.

Colin Whitmore (C)

University of Minnesota, Division of Transplantation, Minneapolis, Minnesota.

Chase J Wehrle (CJ)

Cleveland Clinic, Division of Transplantation, Cleveland, Ohio.

Federico Aucejo (F)

Cleveland Clinic, Division of Transplantation, Cleveland, Ohio.

Ekaterina Fedorova (E)

University of Wisconsin, Division of Transplant Surgery, Madison, Wisconsin.

David Aufhauser (D)

University of Wisconsin, Division of Transplant Surgery, Madison, Wisconsin.

Ram Subramanian (R)

Emory University, Division of Transplantation, Atlanta, Georgia.

Marwan M Kazimi (MM)

Emory University, Division of Transplantation, Atlanta, Georgia.

Valmiki Maharaj (V)

University of Minnesota, Division of Cardiology, Minneapolis, Minnesota.

Elizabeth S Aby (ES)

University of Minnesota, Division of Transplantation, Minneapolis, Minnesota.

Joseph Magliocca (J)

Emory University, Division of Transplantation, Atlanta, Georgia.

Steven C Kim (SC)

Emory University, Division of Transplantation, Atlanta, Georgia.

Classifications MeSH